Org OD 02-0
Based on 1 Customer Validation
Org OD 02-0 (10-Ethenyl-19-norprogesterone) is a selective mPRα/PAQR7 agonist that can cross the blood-brain barrier. Org OD 02-0 targets mPRα with an IC50 of 33.9 nM and activates the PI3K-AKT, MAPK/ERK, and Src signaling pathways. Org OD 02-0 upregulates SERCA2, phosphorylates phospholamban, increases sarcoplasmic reticulum calcium uptake, decreases RhoA/ROCK activity, and induces vascular smooth muscle relaxation and nitric oxide production. Org OD 02-0 can be used for research on Parkinson's disease, glioblastoma, apnea, and hypertension.
For research use only. We do not sell to patients.
- Purity : 99.7%
- CAS No.: 13258-85-0
- Formula: C22H30O2
- Molecular Weight:326.47
-
Storage:Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 6 months , -20°C, 1 month
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biological Activity
-
Chemical Information
-
Solvent & Solubility
- Protocols
- Purity & Documentation
- References
-
Help & FAQs
-
HY-B0257A
DydrogesteroneProgestogen -
HY-111614
Melengestrol acetateContraceptive Agent -
HY-109568
LynestrenolPXR Agonist -
HY-14959
UlipristalSelective Progesterone Receptor Modulator -
HY-13071
NestoronProgesterone Receptor Agonist -
HY-119433
Asoprisnil -
HY-15606
TanaprogetProgesterone Receptor Agonist -
HY-11028
PF-02413873Progesterone Receptor Antagonist -
HY-B1089
Ethynodiol diacetateProgesterone Receptor Agonist -
HY-111614R
Melengestrol acetate (Standard) -
HY-157493
PR antagonist 1PR Antagonist -
HY-16775
VilaprisanSPRM
All Calcium Channel Isoforms
More
Biological Activity
Description
|
mPRα 33.9 nM (IC50) |
Akt |
RhoA |
PI3K |
ROCK |
p38 MAPK |
Src |
ERK |
SERCA2 |
PAQR7 |
In Vitro
Org OD 02-0 binds to recombinant human mPRα in MDA-MB-231 cell membranes with an IC50 of 33.9 nM and an RBA of 257.7% relative to progesterone[2].
Org OD 02-0 (100 nM; incubated at 25 °C for 20 min) activates G protein signaling through hu-mPRα in MDA-MB-231 cell membranes[2].
Org OD 02-0 binds to nPR in the cytosolic fraction of MCF-7 cells with an IC50 of 60.1 nM and an RBA of 12.9% relative to progesterone[2].
Org OD 02-0 (1-100 nM; 10 min) activates MAPK/ERK signaling in MDA-MB-231 cells transfected with hu-mPRα[2].
Org OD 02-0 (100 nM-1 μM; five consecutive days) increases the number of U87 and U251 glioblastoma cells starting from day 3[3].
Org OD 02-0 (100 nM; 24-96 h) increases BrdU incorporation in U87 cells at 24 and 48 h, and increases BrdU incorporation in U251 cells at 24 h[3].
Org OD 02-0 (100 nM; 3-48 h) increases scratch-wound healing migration of U87 and U251 glioblastoma cells[3].
Org OD 02-0 (100 nM; 24 h) increases Transwell invasion of U87 and U251 glioblastoma cells[3].
Org OD 02-0 (100 nM; 5-60 min) induces Src and Akt phosphorylation in U87 and U251 glioblastoma cells[3].
Org OD 02-0 (100 nM; 24 h) reduces 6-OHDA- or MPP+-induced SH-SY5Y cell death in the Hoechst assay[5].
Org OD 02-0 (100 nM; 24 h) exerts neuroprotective effects on SH-SY5Y cells mediated by mPRα, as PAQR7 siRNA completely abolished the protection against 6-OHDA and MPP+[5].
The protective effect of Org OD 02-0 (100 nM; 24 h) against 6-OHDA resistance in SH-SY5Y cells is completely blocked by ERK, PI3K, and AKT inhibitors (AZD6244 (Selumetinib) (HY-50706), Wortmannin (HY-10197), mL-9 (HY-100932))[5].
Org OD 02-0 (20 nM; 15 min) increases ERK phosphorylation in GH3 cells[7].
Org OD 02-0 lacks nPR agonist activity in the MCF-7 nPR reporter gene assay and exhibits weak nPR antagonist activity in the presence of 5 nM progesterone[2].
Org OD 02-0 (100 nM; 10 min) increases AKT phosphorylation without affecting ERK phosphorylation under basal conditions, and increases ERK and AKT phosphorylation after overnight 6-OHDA pre-exposure in SH-SY5Y cells[5].
Org OD-02-0 (5 μM; 20 min) mimics Progesterone (HY-N0437)-induced rhythmic contractions and inhibited high KCl-induced tonic contractions, producing a stronger inhibitory effect than Progesterone in D20 a.m. rat myometrial strips[6].
Org OD 02-0 inhibits PRL secretion from anterior pituitary explants of female Sprague-Dawley rats[7].
Org OD 02-0 (20 nM; 30 min) inhibits PRL release in GH3 cells via pertussis toxin-sensitive Gi protein[7].
Org OD 02-0 (20 nM; 10 min) reduces cAMP accumulation in GH3 cells[7].
Org OD 02-0 (20 nM) increases SERCA protein expression and PLB phosphorylation in human VSMCs via mPRα[4].
Org OD 02-0 (20 nM) promotes SR Ca2+ uptake, reduces cytosolic Ca2+, and induces relaxation of human VSMCs via SERCA2[4].
OD 02-0 (20-100 nM; 20 min) reduces isometric tension in endothelium-denuded human umbilical artery rings through SERCA- and Gi-dependent signaling[4].
OD 02-0 (20 nM) increases SERCA expression and SR Ca2+ uptake in human VSMCs through Gi/MAPK/PI3K-Akt signaling and requires reduced RhoA/ROCK activity[4].
Org OD 02-0 (100 nM) reduces RhoA activation in human umbilical artery VSMCs[10].
Org OD 02-0 (20 nM; 1-4 h) reduces phosphorylation of ROCK at Ser1366 in human umbilical artery VSMCs[10].
Org OD 02-0 (20 nM; 15 min) increases active TGFβ1 in GH3 cells through a Gi-dependent decrease in cAMP and requires mPRα[7].
Org OD 02-0 (100 nM; 30 min-1 h) inhibits PRL release from anterior pituitary explants of female Drd2 KO and WT mice, with a stronger inhibitory effect on Drd2 KO tumor tissue, and increased active TGFB1 only in Drd2 KO pituitaries[8].
Org OD 02-0 (100 nM) attenuates PGF2α-induced calcium increase in human umbilical artery VSMCs[10].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:human glioblastoma cell lines U87 and U251
-
Concentration:100 nM and 1 μM
-
Incubation Time:five consecutive days
-
Result:We observed that both Org OD 02-0 and P4 increased the number of U87 and U251 cells from the third day on when compared to the vehicle.
-
Cell Line:human glioblastoma cell lines U87 and U251
-
Concentration:100 nM
-
Incubation Time:24, 48, 72, and 96 h
-
Result:In U87 cells, Org OD 02-0 (100 nM) increased BrdU incorporation at 24 and 48 h.
In U251 cells, Org OD 02-0 (100 nM) increased BrdU incorporation at 24 h.
-
Cell Line:human glioblastoma cell lines U87 and U251
-
Concentration:100 nM
-
Incubation Time:3, 6, 12, 24, and 48 h
-
Result:Our results show that the agonist significantly increased the number of migrating U87 cells from 3 to 24 h in comparison with the vehicle.
Increased U251 cell migration at 3, 12, and 24 h.
-
Cell Line:human glioblastoma cell lines U87 and U251
-
Concentration:100 nM
-
Incubation Time:24 h
-
Result:Our results show that Org OD 02-0 significantly increased the invading capabilities of both cell lines in comparison with the vehicle.
-
Cell Line:human glioblastoma cell lines U87 and U251
-
Concentration:100 nM
-
Incubation Time:5, 10, 30, 60 min
-
Result:Exposure to Org OD 02-0 induced Src phosphorylation from 5 to 60 min, reaching the highest level at 30 min in both cell lines, and this effect was maintained in U251 cells until 60 min.
Regarding Akt, its highest phosphorylation level was reached at 5 min in both cell lines.
The effect of Src and Akt phosphorylation upon Org OD 02-0 exposure at the time of the highest effect for each kinase was blocked using the inhibitors PP2 (HY-13805) (5 μM) and LY294002 (HY-10108) (1 μM).
-
Cell Line:SH-SY5Y human neuroblastoma cells
-
Concentration:100 nM
-
Incubation Time:24 h
-
Result:100 nM Org OD 02-0 and P4 reduced the fraction of Hoechst-positive nuclei in SH-SY5Y cells exposed to 6-OHDA or MPP+ to levels similar to vehicle controls not exposed to the neurotoxic chemicals.
-
Cell Line:SH-SY5Y human neuroblastoma cells
-
Concentration:100 nM
-
Incubation Time:24 h
-
Result:100 nM Org OD 02-0 significantly decreased cell death.
100 nM R5020 and 100 µM muscimol were ineffective and did not show a neuroprotective action during 6-OHDA or MPP+ 24 h incubations in the Hoechst assay.
PAQR7 siRNA completely abolished the 100 nM Org OD 02-0 protective effect on cell viability in the presence of both 6-OHDA and MPP+.
-
Cell Line:SH-SY5Y human neuroblastoma cells
-
Concentration:100 nM (Org OD 02-0)
-
Incubation Time:10 min (selected from 5, 10, 30 min); overnight pre-exposure to 6-OHDA
-
Result:Following 10 min incubation, 100 nM Org OD 02-0 did not affect ERK phosphorylation but significantly increased AKT phosphorylation.
After overnight 6-OHDA pre-exposure, phosphorylation of both ERK and AKT was significantly increased after Org OD 02-0 incubation.
-
Cell Line:SH-SY5Y human neuroblastoma cells
-
Concentration:100 nM
-
Incubation Time:24 h
-
Result:AZD 6244 (1 mM), Wortmannin (50 nM), and ML-9 (15 mM) completely blocked the 100 nM Org OD 02-0 protective effect on SH-SY5Y cell viability in the Hoechst assay in the presence of 6-OHDA.
-
Cell Line:GH3 cells
-
Concentration:20 nM
-
Incubation Time:15 min
-
Result:Induced a significant increase in ERK phosphorylation.
In Vivo
Org OD 02-0 (4 mg/kg; intraperitoneal injection; single injection) acutely activates membrane progesterone receptors, reducing the frequency of spontaneous apnea in both male and female neonatal rats and decreasing post-sigh apnea frequency in male rats without altering apnea duration[9].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:B6;129S2-Drd2tm1low (female, 8-month-old)[8]
-
Dosage:15 mg/kg
-
Administration:s.c.; single injection
-
Result:A single dose of Org OD 02-0 significantly diminished serum PRL at 15 min and maintained those levels up to 30 min.
-
Animal Model:Sprague-Dawley (male and female; postnatal days 10-12 (P10-P12); body weight 29.0 (3.1) g in males (n=11) and 31.8 (4.0) g in females (n=10) for Org OD 02-0 group)[9]
-
Dosage:4 mg/kg
-
Administration:i.p.; single injection
-
Result:Acute I.P.
Org OD 02-0 4 mg kg−1 reduced the frequency of spontaneous apnoeas in both male and female P10-P12 rats to a similar extent.
It decreased the frequency of post-sigh apnoea only in males.
It did not influence the duration of spontaneous or post-sigh apnoeas.
In female rats, the mPR agonist reduced respiratory frequency compared with females receiving vehicle or the nPR agonist R5020 (Promegestone) (HY-119384).
Chemical Information
-
CAS No. 13258-85-0
-
Appearance Solid
-
Molecular Weight 326.47
-
Formula C22H30O2
-
Color White to off-white
-
SMILES
CC([C@H]1CC[C@@]2([H])[C@]3([H])CCC4=CC(CC[C@]4(C=C)[C@@]3([H])CC[C@]12C)=O)=O
-
Synonyms
10-Ethenyl-19-norprogesterone
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month
Solvent & Solubility
In Vitro:
DMSO : 24 mg/mL (73.51 mM; Need ultrasonic and warming; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Ethanol : 3.3 mg/mL (10.11 mM; Need ultrasonic and warming)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Purity & Documentation
-
Data Sheet (310 KB)
-
SDS (392 KB)
- English - EN (392 KB)
- Français - FR (392 KB)
- Deutsch - DE (392 KB)
- Norwegian - NO (392 KB)
- Español - ES (392 KB)
- Swedish - SV (392 KB)
- Italian - IT (392 KB)
- Korean - KR (392 KB)
- Portuguese - PT (392 KB)
-
Handling Instructions (2659 KB)
References
[2]. Kelder J, et al. Comparison between steroid binding to membrane progesterone receptor alpha (mPRalpha) and to nuclear progesterone receptor: correlation with physicochemical properties assessed by comparative molecular field analysis and identification of mPRalpha-specific agonists. Steroids. 2010 Apr;75(4-5):314-22. [Content Brief]
[4]. Pang Y, et al. Involvement of sarco/endoplasmic reticulum Ca-ATPase (SERCA) in mPRα (PAQR7)-mediated progesterone induction of vascular smooth muscle relaxation. American journal of physiology. Endocrinology and metabolism. 2021 Mar 01;320(3):E453-E466. [Content Brief]
[5]. Castelnovo LF, et al. Progesterone exerts a neuroprotective action in a Parkinson's disease human cell model through membrane progesterone receptor α (mPRα/PAQR7). Frontiers in endocrinology. 2023;14:1125962. [Content Brief]
[7]. Camilletti MA, et al. Participation of membrane progesterone receptor α in the inhibitory effect of progesterone on prolactin secretion. Journal of Neuroendocrinology. 2018 Sep;30(9):e12614. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| Ethanol / DMSO | 1 mM | 3.0631 mL | 15.3153 mL | 30.6307 mL | 76.5767 mL |
| 5 mM | 0.6126 mL | 3.0631 mL | 6.1261 mL | 15.3153 mL | |
| 10 mM | 0.3063 mL | 1.5315 mL | 3.0631 mL | 7.6577 mL | |
| DMSO | 15 mM | 0.2042 mL | 1.0210 mL | 2.0420 mL | 5.1051 mL |
| 20 mM | 0.1532 mL | 0.7658 mL | 1.5315 mL | 3.8288 mL | |
| 25 mM | 0.1225 mL | 0.6126 mL | 1.2252 mL | 3.0631 mL | |
| 30 mM | 0.1021 mL | 0.5105 mL | 1.0210 mL | 2.5526 mL | |
| 40 mM | 0.0766 mL | 0.3829 mL | 0.7658 mL | 1.9144 mL | |
| 50 mM | 0.0613 mL | 0.3063 mL | 0.6126 mL | 1.5315 mL | |
| 60 mM | 0.0511 mL | 0.2553 mL | 0.5105 mL | 1.2763 mL |
Org OD 02-0 Related Classifications
HY-131547 Related Classifications
Powered by Bioz